Pulse Biosciences, Inc.
NASDAQ:PLSEMedical - Instruments & Supplies
+$0.97 today
- Market cap
- $3.37B
- Beta
- 1.66
- P/E (TTM)
- -24.0
- EPS (TTM)
- -$1.10
Volume 0.33M
Average 0.31M
PLSE Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Pulse Biosciences, Inc.NASDAQ: PLSE
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity falls 4.8% from a year ago
Total equity stood at $99.5M at the end of Q2 FY2026, down 4.8% from a year earlier and up 50.1% from the prior quarter.
Context
- Total equity amounted to 86.1% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -4.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 80.66M USD
- Year-over-year change
- -29.8%
- 4-year CAGR
- +22.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 80.66M | -29.8% |
| FY2024 | 2024-12-31 | 114.86M | +158.9% |
| FY2023 | 2023-12-31 | 44.36M | +2073.3% |
| FY2022 | 2022-12-31 | (2.25M) | -106.3% |
| FY2021 | 2021-12-31 | 35.69M | — |
Total Equity vs competitors
How PLSE compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -4.8% is the 7th highest of 11, against a peer median of +11.6%.
- Total equity amounts to 86.1% of total assets for PLSE, versus a peer median of 77.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.2B USD | -8.2% | -6.7% | 64.9% | |
| Jun 2026 | $1.17B USD | +286.7% | +88.5% | 96.6% | |
| Jun 2026 | $903.12M USD | +3830.2% | -37.4% | 82.5% | |
| Mar 2026 | €456.28M EUR | -15.0% | +31.4% | 83.9% | |
| Apr 2026 | $352.37M USD | +0.7% | +0.8% | 78.1% | |
| Mar 2026 | $330.72M USD | -8.6% | -8.3% | 42.0% | |
| Jan 2026 | $287.99M USD | +211.7% | — | 75.9% | |
| Mar 2026 | $271.25M USD | -13.5% | +180.7% | 89.1% | |
| Jun 2026 | $176.44M USD | +22.6% | -5.8% | 66.6% | |
| Jun 2026 | $99.5M USD | -4.8% | — | 86.1% | |
| Mar 2026 | $15.04M USD | +3928.6% | — | 21.4% | |
| Peer median (excluding PLSE) | — | +11.6% | -2.5% | 77.0% | |
Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.61M | 61.14M | 44.37M | 118.04M | 80.74M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 61K | 0 | 0 | 0 | 274K |
| Inventory | 5.82M | 0 | 0 | 0 | 136K |
| Other Current Assets | 0 | 1.01M | 963K | 1.41M | 2.28M |
| Total Current Assets | 36.63M | 62.15M | 45.33M | 119.45M | 83.42M |
| Property, Plant & Equipment (Net) | 11.25M | 10.02M | 8.78M | 8.32M | 7.06M |
| Goodwill | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M |
| Intangible Assets | 3.22M | 2.55M | 1.89M | 1.22M | 575K |
| Long-term Investments | (3.26M) | (2.73M) | 1.89M | 0 | 0 |
| Tax Assets | 3.26M | 2.73M | 0 | 0 | 1.58M |
| Other Non-current Assets | 365K | 365K | (1.52M) | 677K | 691K |
| Total Non-current Assets | 17.62M | 15.73M | 13.83M | 13.01M | 12.69M |
| Total Assets | 54.25M | 77.88M | 59.15M | 132.46M | 96.11M |
| Account Payables | 2.9M | 1.57M | 1.84M | 1.67M | 2.78M |
| Short-term Debt | 436K | 917K | 0 | 0 | 1.57M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 16K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.46M | 50K | 3.2M | 1.2M | 1.6M |
| Total Current Liabilities | 8.52M | 5.98M | 6.71M | 10.06M | 7.92M |
| Long-term Debt | 0 | 65M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.58M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 10.04M | 74.14M | 8.09M | 7.54M | 7.54M |
| Total Liabilities | 18.56M | 80.13M | 14.79M | 17.6M | 15.46M |
| Common Stock | 29K | 37K | 55K | 66K | 68K |
| Retained Earnings | (236.2M) | (294.71M) | (336.92M) | (390.5M) | (463.28M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 35.69M | (2.25M) | 44.36M | 114.86M | 80.66M |
| Total Debt | 11.25M | 75.96M | 9.14M | 8.9M | 7.53M |
| Net Debt | (17.36M) | 14.82M | (35.22M) | (109.14M) | (73.21M) |
Pulse Biosciences, Inc.
NASDAQ:PLSE
Intrinsic Alpha fair value
Locked
Current Price
$45.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.